Orient Pharma Co. Ltd.
Orient Pharma Co., Ltd. engages in the development of new drugs in Taiwan and internationally. It offers cardiovascular drugs, such as Pitator and Tonvasca for lipid suppression, as well as Zulitor, a lipid lowering drug; psychotropic drugs, including Trokendi XR extended, Methydur, and powder and solvent for prolonged-release suspension for injection. The company was founded in 2008 and is based… Read more
Orient Pharma Co. Ltd. (4166) - Total Assets
Latest total assets as of June 2024: NT$2.60 Billion TWD
Based on the latest financial reports, Orient Pharma Co. Ltd. (4166) holds total assets worth NT$2.60 Billion TWD as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Orient Pharma Co. Ltd. - Total Assets Trend (2019–2023)
This chart illustrates how Orient Pharma Co. Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Orient Pharma Co. Ltd. - Asset Composition Analysis
Current Asset Composition (December 2023)
Orient Pharma Co. Ltd.'s total assets of NT$2.60 Billion consist of 24.3% current assets and 75.7% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 3.3% |
| Accounts Receivable | NT$245.46 Million | 9.6% |
| Inventory | NT$233.97 Million | 9.1% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$532.66 Million | 20.8% |
| Goodwill | NT$1.00 | 0.0% |
Asset Composition Trend (2019–2023)
This chart illustrates how Orient Pharma Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Orient Pharma Co. Ltd.'s current assets represent 24.3% of total assets in 2023, an increase from 16.5% in 2019.
- Cash Position: Cash and equivalents constituted 3.3% of total assets in 2023, up from 2.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 20.0% of total assets, an increase from 1.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 20.8% of total assets.
Orient Pharma Co. Ltd. Competitors by Total Assets
Key competitors of Orient Pharma Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Orient Pharma Co. Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Orient Pharma Co. Ltd. generates 0.35x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Orient Pharma Co. Ltd. generates $ 0.87 in net profit.
Orient Pharma Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.32 | 1.06 | 1.51 |
| Quick Ratio | 0.83 | 0.69 | 0.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$178.50 Million | NT$ 31.04 Million | NT$ 141.16 Million |
Orient Pharma Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between Orient Pharma Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.62 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 38.7% |
| Total Assets | NT$2.56 Billion |
| Market Capitalization | $41.55 Million USD |
Valuation Analysis
Below Book Valuation: The market values Orient Pharma Co. Ltd.'s assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Orient Pharma Co. Ltd.'s assets grew by 38.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Orient Pharma Co. Ltd. (2019–2023)
The table below shows the annual total assets of Orient Pharma Co. Ltd. from 2019 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | NT$2.56 Billion | +38.70% |
| 2022-12-31 | NT$1.85 Billion | +4.75% |
| 2021-12-31 | NT$1.76 Billion | +1.15% |
| 2020-12-31 | NT$1.74 Billion | +11.53% |
| 2019-12-31 | NT$1.56 Billion | -- |